Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year
Cash runway extended into 2026 following successful completion of equity offering in June
Read more at globenewswire.comXenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
